Immunomodulatory effects of galectin-1 in patients with chronic lymphocytic leukemia

MILOŠ KOSTIĆ1, TANJA DŽOPLIĆ1, GORAN MARJANOVIĆ1,2, IVANA UROSEVIĆ3,4, IVANA MILOSEVIĆ3,4

1Department of Immunology, Medical Faculty of Nis, University of Nis, Nis, Serbia
2Department of Hematology and Clinical Immunology, Clinical Centre Nis, Nis, Serbia
3Department of Hematology, University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia
4Clinical Centre of Vojvodina, Hematology Clinic, Novi Sad, Serbia

Abstract

Galectin-1 (Gal-1) has been implicated in the progression of chronic lymphocytic leukemia (CLL) but also the development of immunodeficiency, which commonly accompany this malignancy. In this in vitro study, we investigated the effects of Gal-1 inhibition in the sera of immunocompromised CLL patients on immunomodulating properties of dendritic cells (DCs). DCs derived from peripheral blood mononuclear cells were treated with a healthy serum, CLL serum as well as the combination of CLL serum and Gal-1 inhibitor (OTX008). Following the treatment, the expression levels of DC maturation markers (CD80, CD83, CD86 and IDO-1) were determined as well as their cytokine profile and the ability to polarize the immune response in co-cultures with CD4+ T cells. After treatment with CLL serum, an increase in interleukin (IL)-10 production was observed in both DC cultures and co-cultures with CD4+ T cells. OTX008 caused a reduction in IL-10 production as well as IL-2, but no significant alteration in the expression of DC maturation markers or T regulatory cell (Treg) frequency was observed. The results of our study suggest that Gal-1 from CLL serum give rise to a specific IL-10+ CD4+ T cell phenotype, other than Treg, that could mediate immunodeficiency development in CLL patients.

Key words: galectin-1, immunodeficiency, chronic lymphocytic leukemia, OTX008, dendritic cell.

Introduction

Chronic lymphocytic leukemia (CLL) is a lymphoproliferative disease characterized by the accumulation of monoclonal CD5+ B cells in the bone marrow, blood and peripheral lymph organs. During the disease progression, a number of accompanying symptoms can occur including autoimmune phenomena, secondary malignancies, and increased susceptibility to infection. Infectious complications continue to be one of the leading causes of comorbidity and mortality in CLL patients [1, 2]. Accordingly, numerous defects in the patients’ immune system have been identified, including hypogammaglobulinemia, abnormalities of cellular immunity, defects of the complement system, and neutrophil phagocytic activity [3].

Beside CLL, various other lymphoproliferative disorders such as Hodgkin lymphoma and multiple myeloma are also commonly accompanied by immunodeficiency, and it has been recently suggested that galactin-1 (Gal-1) may be implicated in the development of such a condition [4-6]. Galactins are an evolutionarily conserved family of β-galactoside binding lectins, ubiquitously distributed in the organism, that can be found both intra- and extracelularly. In humans, 12 different galactin classes have been described, all of which have been proposed to play an important role in regulating the immune response [7]. Specifically, Gal-1 was shown to perform immunosuppressive functions by antagonizing activation signals derived from the T cell receptor (TCR) during T cell activation, but also by inducing apoptosis of activated T cells and expansion of regulatory T and B cells [8-12].

In CLL patients elevated plasma levels of Gal-1 were documented, and associated with disease progression, given that Gal-1 levels were higher in the Binet A clinical stage compared to the stage Binet C. Gal-1 levels were also higher in the patients with poorer disease prognosis based on the expression of ZAP70 and CD38 molecules [6]. Interestingly, activation of CLL clones in the presence of Gal-1 resulted in the production of the immunosuppressive cytokine IL-10, which is important in survival of the malignant cells [6]. Taken together, these results suggest that Gal-1 may be a relevant factor in the disease progression but also mediate the development of immunodeficiency.

Considering these data, we conducted an in vitro study in which we examined the effects of Gal-1 inhibition in...
CLL patients with clinically manifested immunodeficiency. The experimental effects of Gal-1 inhibition were estimated in the experimental model of dendritic cells (DCs) co-cultured with allogenic CD4+ T cells, considering that DCs are critical in mounting and shaping an adaptive immune response.

Material and methods

Dendritic cells cultivation and experimental protocols

The immunomodulatory properties of Gal-1 in the serum of CLL patients were tested in DC cultures obtained from peripheral blood mononuclear cells (PBMCs). Briefly, PBMCs were isolated from buffy coat of the healthy volunteer blood donor, using centrifugation over a Ficoll-Hypaque density gradient (Histopaque-1077; Sigma-Aldrich, St. Louis, Missouri, USA). Upon isolation, PBMCs were resuspended in 5 ml of cell culture medium – RPMI-1640 medium supplemented with 2.05 mM L-glutamine, 25 mM HEPES (Sigma-Aldrich, St. Louis, Missouri, USA), 10% inactivated fetal bovine serum (FBS) (Capricorn Scientific GmbH, Ebsdorfergrund, Germany) and 50 μM 2-mercaptoethanol (Sigma-Aldrich, St. Louis, Missouri, USA), and then seeded into 25 ml cell culture flasks (30 × 10^6 cells per flask). After brief incubation at 37°C in 5% CO_2 at 95% humidity for 90 min, supernatants were discarded and the flasks were rinsed repeatedly to eliminate non-adherent cells. Then, 5 ml of fresh RPMI-1640 medium with 10% FBS and 50 μM 2-mercaptoethanol, enriched with human recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) (100 ng/ml) and interleukin (IL)-4 (20 ng/ml) (both obtained from Sigma-Aldrich, St. Louis, Missouri, USA), and then seeded into 25 ml cell culture flasks (30 × 10^6 cells per flask). After brief incubation at 37°C in 5% CO_2 at 95% humidity for 90 min, supernatants were discarded and the flasks were rinsed repeatedly to eliminate non-adherent cells.

Evaluation of DC maturation markers

Dendritic cell phenotype alterations were investigated by the expression of DC maturation markers – CD80, CD83 and CD86 molecules, and the enzyme indolamine 2,3-dioxygenase 1 (IDO-1), using flow cytometry. After washing, the cells were incubated in stain buffer (BD Biosciences, Franklin Lakes, New Jersey, USA) for 30 min at room temperature with fluorochrome conjugated monoclonal antibodies. The following antibodies were used: anti-CD80*FITC*, anti-CD83*PE*, and anti-CD86*PE* (R&D Systems, Minneapolis, Minnesota, USA). In order to block the non-specific antibody binding, stain buffer was supplemented with 10% human inactivated AB serum. For intracellular staining, cells were first permeabilized and fixed using a Fixation/Permeabilization Kit (BD Biosciences, Franklin Lakes, New Jersey, USA) according to the manufacturer’s instructions, and then stained with anti-IDO-1*APC* (R&D Systems, Minneapolis, Minnesota, USA). After washing, samples were analyzed on a BD LSRFortessa (BD Biosciences, Franklin Lakes, New Jersey, USA) according to the instructions provided. The demographic characteristics of the study participants are given in Table 1.

Evaluation of DC immunomodulatory properties

The effects of sera on the immunomodulatory properties of DC were examined. The research was approved by the Ethical Committee of the Clinical Center Nis, Serbia under identification number 35110/11.

Sera used in the experiment

In the experiment, sera of healthy donors and CLL patients with clinically manifested immunodeficiency were used. Previously, Gal-1 serum level was determined using the Human Galectin-1 Quantikine ELISA kit (R&D Systems, Minneapolis, Minnesota, USA) according to the instructions provided. The demographic characteristics of the study participants are given in Table 1.

Table 1. Demographic characteristics of study participants

| Gender | Age (years)* | Disease duration (years)* | Gal-1 (pg/ml)** | Immunodeficiency | Clinical criteria | IgG (g/l)** | IgM (g/l)** | IgA (g/l)** |
|--------|-------------|--------------------------|----------------|-----------------|-----------------|-------------|-------------|-------------|
| Healthy controls | females | 60 (52-68) | NA | 25.62 ±8.19 | ≤ 2 bacterial infections per year | 12.24 ±2.11 | 1.80 ±0.42 | 2.76 ±0.51 |
| CLL patients | females | 67 (58-77) | 2 (1-5) | 64.74 ±16.20 | ≥ 3 bacterial infections per year | 4.42 ±2.01 | 0.77 ±0.59 | 0.38 ±0.33 |

*Mean (range), ‡ mean ±SD, ‡ reference values (ref.) according to the Center for Medical Biochemistry of the Clinical Center Nis, Serbia.

| Gender | Age (years)* | Disease duration (years)* | Gal-1 (pg/ml)** | Immunodeficiency | Clinical criteria | IgG (g/l)** | IgM (g/l)** | IgA (g/l)** |
|--------|-------------|--------------------------|----------------|-----------------|-----------------|-------------|-------------|-------------|
| Healthy controls | females | 60 (52-68) | NA | 25.62 ±8.19 | ≤ 2 bacterial infections per year | 12.24 ±2.11 | 1.80 ±0.42 | 2.76 ±0.51 |
| CLL patients | females | 67 (58-77) | 2 (1-5) | 64.74 ±16.20 | ≥ 3 bacterial infections per year | 4.42 ±2.01 | 0.77 ±0.59 | 0.38 ±0.33 |

*Mean (range), ‡ mean ±SD, ‡ reference values (ref.) according to the Center for Medical Biochemistry of the Clinical Center Nis, Serbia.

| Gender | Age (years)* | Disease duration (years)* | Gal-1 (pg/ml)** | Immunodeficiency | Clinical criteria | IgG (g/l)** | IgM (g/l)** | IgA (g/l)** |
|--------|-------------|--------------------------|----------------|-----------------|-----------------|-------------|-------------|-------------|
| Healthy controls | females | 60 (52-68) | NA | 25.62 ±8.19 | ≤ 2 bacterial infections per year | 12.24 ±2.11 | 1.80 ±0.42 | 2.76 ±0.51 |
| CLL patients | females | 67 (58-77) | 2 (1-5) | 64.74 ±16.20 | ≥ 3 bacterial infections per year | 4.42 ±2.01 | 0.77 ±0.59 | 0.38 ±0.33 |

*Mean (range), ‡ mean ±SD, ‡ reference values (ref.) according to the Center for Medical Biochemistry of the Clinical Center Nis, Serbia.

| Gender | Age (years)* | Disease duration (years)* | Gal-1 (pg/ml)** | Immunodeficiency | Clinical criteria | IgG (g/l)** | IgM (g/l)** | IgA (g/l)** |
|--------|-------------|--------------------------|----------------|-----------------|-----------------|-------------|-------------|-------------|
| Healthy controls | females | 60 (52-68) | NA | 25.62 ±8.19 | ≤ 2 bacterial infections per year | 12.24 ±2.11 | 1.80 ±0.42 | 2.76 ±0.51 |
| CLL patients | females | 67 (58-77) | 2 (1-5) | 64.74 ±16.20 | ≥ 3 bacterial infections per year | 4.42 ±2.01 | 0.77 ±0.59 | 0.38 ±0.33 |

*Mean (range), ‡ mean ±SD, ‡ reference values (ref.) according to the Center for Medical Biochemistry of the Clinical Center Nis, Serbia.
IL-10, IL-12 and transforming growth factor β (TGF-β) levels in cell culture supernatants. The following ELISA kits were used: Human IL-2 Quantikine ELISA Kit, Human IL-4 Quantikine ELISA Kit, Human IL-10 Quantikine ELISA Kit, Human IL-12p70 Quantikine ELISA Kit, and Human TGF-β Quantikine ELISA Kit (all obtained from R&D Systems, Minneapolis, Minnesota, USA) according to the manufacturer’s instructions.

Evaluation of DC ability to polarize the immune response

The study of serum effects on DC ability to polarize the immune response was conducted in the co-cultures with allogeneic CD4+ T cells. Human CD4+ T cells were isolated as a negative fraction by immunomagnetic sorting from PBMCs obtained from buffy coat of a healthy voluntary blood donor using an EasySep Human CD4+ T Cell Isolation Kit (Stemcell Technologies, Vancouver, Canada) according to the instructions provided. After isolation, 1 × 10^5 CD4+ T cells were co-cultured with 1 × 10^4 DCs in a 96-well U-bottom plate for 5 days. After the fifth day, cell cultures were treated with phorbol myristate acetate – PMA (20 ng/ml) and ionomycin (100 ng/ml) (Sigma-Aldrich, St. Louis, Missouri, USA) for 8 h to stimulate cytokine production. Supernatants were collected and IL-2, IL-4, IL-10, IL-17, interferon γ (IFN-γ) and TGF-β levels were determined using the following ELISA kits: Human IL-2 Quantikine ELISA Kit, Human IFN-γ Quantikine ELISA Kit, Human IL-4 Quantikine ELISA Kit, Human IL-10 Quantikine ELISA Kit, Human IL-17 Quantikine ELISA Kit, and Human TGF-β Quantikine ELISA Kit (all obtained from R&D Systems, Minneapolis, Minnesota, USA) according to the manufacturer’s instructions. In the remaining cells the frequency of T regulatory cells (Tregs) was estimated using flow cytometry. Cells were washed in stain buffer (BD Biosciences, Franklin Lakes, New Jersey, USA), and then permeabilized and fixed using Transcription Factor Phospho Buffer Set (BD Biosciences, Franklin Lakes, New Jersey, USA). To identify Tregs, anti-CD4^{FITC}, anti-CD25^{APC}, and anti-FoxP3^{PE} antibodies (all obtained from BD Biosciences, Franklin Lakes, New Jersey, USA) were applied. After washing, sample analysis was performed on a BD LSRFortessa using BD FACSDiva software.

Statistical analyses

All statistical analyses were performed in SPSS v17.0 (SPSS Inc., Chicago, IL, USA). The results are presented as the mean values obtained from three experiments ± standard deviation (SD). The intergroup differences were established using one-way analysis of variance (ANOVA) with Tukey’s HSD test, and p values less than 0.05 were considered statistically significant.

Results

Effects of Gal-1 inhibitor (OTX008) on phenotype and immunomodulatory properties of DCs

The allosteric inhibitor OTX008 was used to block Gal-1 in the CLL patient serum. By determining the expression level of DC maturation markers (CD80, CD83, CD86) and IDO-1, it was found that OTX008, per se, did not modify these phenotype characteristics of DCs (Fig. 1).

![Fig. 1. Effects of OTX008 on DC maturation markers: DCs were treated with OTX008 (50 μM) for 48 h and then the expression level of DC maturation markers CD80, CD83, CD86, and IDO-1 was determined by flow cytometry (DC – untreated dendritic cells)](image-url)
In DC co-cultures with allogeneic CD4+ T cells, OTX008 did not cause significant changes in the cytokine profile of DCs (Fig. 2A), or significant alterations in the CD4+ T cell polarization profile (Fig. 2B).

**Effects of CLL serum on the phenotype and immunomodulatory properties of DCs**

The effects of CLL serum on DC ability to modulate the immune response were estimated by their phenotype and cytokine profile, as well as the polarization profile of CD4+ T cells in co-cultures. It was found that CLL serum did not induce significant alterations in the expression of DC maturation markers, in contrast to LPS treatment (Fig. 3).

However, treatment with CLL serum resulted in a statistically significant increase in production of the immunosuppressive cytokine IL-10, in both pure DC cultures (Fig. 4A) and DC co-cultures with CD4+ T cells (Fig. 4B). At the same time, in the co-cultures, an increase in IL-2 production was observed (Fig. 4B). The production of other tested cytokines was not significantly different when compared to untreated DC and/or DC treated with control serum.

**Effects of Gal-1 inhibition on phenotype and immunomodulatory properties of DCs**

Dendritic cells were also treated with the combination of CLL serum and OTX008 to evaluate the immunomodulatory effect of serum Gal-1, as well as the effects of its inhibition. No significant alterations of DC maturation markers were documented (Fig. 5).

However, OTX008 treatment resulted in decreased production of IL-10 in both DC cultures (Fig. 6A) and co-cultures with CD4+ T cells (Fig. 6B) to levels that were comparable to the healthy control. In DC co-cultures with CD4+ T cells reduced production of IL-2 was also observed following OTX008 treatment. Interestingly, the treatment with control serum significantly decreased the IL-17 level compared to the treatment with CLL serum with or without OTX008 (Fig. 6B).

**Effects of Gal-1 inhibition on Treg expansion**

In order to examine the potential immunosuppressive properties of serum Gal-1, Treg frequency was determined
Fig. 3. Effects of CLL serum on DC maturation markers: DCs were treated with 30% inactivated serum of healthy subjects, CLL patients, and LPS (1 ng/ml) for 48 h. The expression level of DC maturation markers CD80, CD83, CD86, and IDO-1 was determined by flow cytometry (*p < 0.05, **p < 0.01 vs. CLL) (DC – untreated dendritic cells, Control – serum of healthy subjects, CLL – serum of CLL patients).

Fig. 4. Effects of sera on DC cytokine profile (A) and their ability to polarize the immune response in co-cultures with CD4+ T cells (B): DCs were treated with 30% inactivated serum of healthy subjects, CLL patients, and LPS (1 ng/ml) for 48 h, then cytokine levels were determined in the collected supernatants (A). Treated DCs were co-cultured with CD4+ T cells for 5 more days, and prior cytokine determination, stimulated with PMA (20 ng/ml) and ionomycin (100 ng/ml) for 8 h (B) (*p < 0.05, **p < 0.01 vs. CLL) (DC – untreated dendritic cells, Control – serum of healthy subjects, CLL – serum of CLL patients, CD4+ T Lymphocytes alone).
Immunomodulatory effects of galectin-1 in patients with chronic lymphocytic leukemia

Fig. 5. Effects of Gal-1 inhibition on DC maturation markers: DCs were treated with 30% inactivated serum of healthy subjects, CLL patients, and the combination of CLL serum and OTX008 (50 μM) for 48 h. The expression level of DC maturation markers CD80, CD83, CD86, and IDO-1 was determined by flow cytometry (Control – serum of healthy subjects, CLL – serum of CLL patients, CLL + OTX008 – serum of CLL patients in the combination with OTX008).

Fig. 6. Effects of Gal-1 inhibition on DC cytokine profile (A) and their ability to polarize the immune response in co-culture with CD4+ T cells (B); DCs were treated with 30% inactivated serum of healthy subjects, CLL patients, and the combination of CLL serum and OTX008 (50 μM) for 48 h, then cytokine levels were determined in the collected supernatants (A). Treated DCs were co-cultured with CD4+ T cells for 5 more days, and prior cytokine determination, stimulated with PMA (20 ng/ml) and ionomycin (100 ng/ml) for 8 h (B) (**p < 0.01 vs. CLL + OTX008) (Control – serum of healthy subjects, CLL – serum of CLL patients, CLL + OTX008 – serum of CLL patients in the combination with OTX008).
in DC co-cultures with CD4+ T cells, but no statistically significant intergroup differences were observed (Fig. 7).

Discussion

Considering the well-known immunosuppressive properties of Gal-1 on the constituents of both innate and acquired immunity [13], in the conducted study, we examined the relevance of Gal-1 in the pathogenesis of immunodeficiency in the patients with CLL, as previously suggested in other lymphoproliferative diseases [4, 14]. DCs play a key role in defining the characteristics of the acquired immune response, so we treated DCs with sera of healthy subjects and CLL patients with clinically manifested immunodeficiency in order to evaluate the effects of serum Gal-1 as well as the effects of its blockade with the allosteric inhibitor OTX008.

OTX008, per se, did not exert significant immunomodulatory properties, given that it did not alter the phenotype characteristics of DCs, their cytokine profile or ability to polarize the immune response when co-cultured with allogenic CD4+ T cells.

By examining the effects of patients’ sera on the immunomodulatory properties of DCs, no significant changes in the expression level of DC maturation markers were documented. The expression of IDO-1, which is suggested to be an important indicator of the tolerogenic DC phenotype [15], was also unaltered. On the other hand, a statistically significant increase in the production of the immunosuppressive cytokine IL-10 was present in both pure DC cultures and co-cultures with CD4+ T cells. OTX008 was able to decrease IL-10 production to a level that was no longer different from that in healthy subjects. Such a finding might indicate that serum Gal-1 primes...
DCs to polarize the immune response toward enhanced IL-10 production. Besides CLL, similar effects of Gal-1 on DCs have been reported in the literature. In particular, Ilarregui et al. observed that CD4+ T cells when co-cultured with DCs pretreated with LPS and Gal-1 produced a significantly higher amount of IL-10 than those co-cultured with DCs pretreated with LPS alone [16]. In order to identify the potential phenotype of IL-10 producing CD4+ T cells induced by the serum of CLL patients, we examined the frequency of Tregs, identified as CD4+CD25+FoxP3+ T cells, but no significant intergroup variations were observed. This indicates that Gal-1 from sera of CLL patients could modulate DC phenotype in a manner that promotes CD4+ T cell differentiation toward IL-10+ but FoxP3 phenotype. Potential candidates could be type 1 regulatory T cells (Tr1), which exert immunosuppressive functions via IL-10 production but do not express FoxP3 transcription factor [17]. Interestingly, other authors have also shown that pretreatment of DC with Gal-1 did not lead to the expansion of conventional Treg yet stimulated differentiation of IL-10+ CD4+ T cells that had the ability to suppress T cell proliferation in a dose-dependent manner, whereby this effect was lost by the use of IL-10 neutralizing antibodies [16]. By direct binding to the CD45 molecule on the T cell surface, Gal-1 could also enhance IL-10 secretion and, at the same time, increase the expression of inhibitory co-stimulators including cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed death 1 (PD-1) [18]. In CLL, elevated serum levels of IL-10 were indeed observed and correlated with biochemical parameters of the disease progression [lactate dehydrogenase (LDH), β2 microglobulin], disease clinical stage and overall survival [19]. In addition, IL-10 is a cytokine directly involved in the disease progression considering that it has been shown that IL-10 could impair the antitumor activity of the immune system against the malignant CLL clone [20]. Unfortunately, currently there are no literature data regarding the number and function of Tr1 in CLL patients.

Another significant finding of our study was that DCs pretreated with the sera of CLL patients enhanced IL-2 production when co-cultured with CD4+ T cells. This effect was neutralized by OTX008, suggesting Gal-1 involvement in this process. Such a finding may seem paradoxical considering that IL-2 is the main factor in promoting the T cell mediated immune response. However, regardless of its immunosuppressive effects, Gal-1 was also shown to stimulate the proliferation of naive T cells, but the significance of IL-2 in this process was not examined, and nor was the phenotype of expanded cells [21]. Accordingly, IL-2 should be reviewed in the broader context of the microenvironment and the presence of other signals, considering that it might exert dual functions – in addition to the expansion of effector T cells, IL-2 could also stimulate the expansion of T cells with immunosuppressive functions [22, 23]. In particular, IL-2 induced expression of transcription factor STAT-5 has been shown to stimulate IL-10 production in FoxP3+ T cells [24], and in vitro induce Tr1 expansion [25]. However, the production of IL-2 in Tr1 is still controversial. Some authors claim that these cells produce relatively small amounts of this cytokine [26], but there are also data suggesting that IL-2 secretion by Tr1 allows the expansion of conventional Treg, and thus it is important for immunosuppressive properties of Tr1 [27].

The inhibition of serum Gal-1 in patients with CLL in DC co-cultures with CD4+ T cells did not significantly alter the secretion of IL-4, IL-17, TGF-β, and IFN-γ. In concordance, others have also indicated that DC pretreatment with Gal-1 did not modify IL-4 and TGF-β levels when co-cultured with CD4+ T cells. However, in contrast to our study, it was suggested that Gal-1 exerts immunosuppressive effects at least partially by suppressing the production of IFN-γ [16]. Another interesting finding was enhanced IL-17 production in co-cultures with CLL serum with or without OTX008. Although suggesting that Gal-1 has no influence on IL-17 production, this finding may indicate that IL-17 is an important factor in CLL pathogenesis, and some supporting data were reported [28, 29].

**Conclusions**

The results of our study suggest that Gal-1 could be implicated in the development of immunodeficiency in CLL patients by promoting alterations in DC phenotype that support the differentiation of a specific subset of IL-10 secreting CD4+ T cells, an effect that could be blocked by the Gal-1 inhibitor OTX008.

**Funding**

This work was supported by the Ministry of Education, Science and Technological Development of the Republic of Serbia, under project number 41018 and the Medical Faculty, University of Nis, Serbia under project number 30.

**Acknowledgments**

This paper was supported by the Ministry of Education, Science and Technological Development of the Republic of Serbia, under project number 41018 and the Medical Faculty, University of Nis, Serbia under project number 30.

*The authors declare no conflict of interest.*

**References**

1. Kipps TJ, Stevenson FK, Wu CJ, et al. (2017): Chronic lymphocytic leukaemia. Nat Rev Dis Primers 3: 16096.

2. Molica S (1994): Infections in chronic lymphocytic leukaemia: risk factors, and impact on survival, and treatment. Leuk Lymphoma 13: 203-214.
3. Nosari A (2012): Infectious complications in chronic lymphocytic leukemia. Medit J Hematol Infect Dis 4: e2012070.
4. Ouyang J, Plütschow A, Pogge von Strandmann E, et al. (2013): Galectin-1 serum levels reflect tumor burden and adverse clinical features in classical Hodgkin lymphoma. Blood 121: 3431-3433.
5. Storti P, Marchica V, Giuliani N (2017): Role of galectins in multiple myeloma. Int J Mol Sci 18: E2740.
6. Croci DO, Morande PE, Dergan-Dylon S, et al. (2013): Nurse-like cells control the activity of chronic lymphocytic leukemia B cells via galectin-1. Leukemia 27: 1413-1416.
7. Brinchmann MF, Patel DM, Iversen MH (2018): The role of galectins as modulators of metabolism and inflammation. Mediators Inflamm 2018: 9186940.
8. Perillo NL, Pace KE, Seithammer JJ, Baum LG (1995): Apoptosis of T cells mediated by galectin-1. Nature 378: 736-739.
9. Endharti AT, Zhou YW, Nakashima I, Suzuki H (2005): Galectin-1 supports survival of naive T cells without promoting cell proliferation. Eur J Immunol 35: 86-97.
10. Chung CD, Patel VP, Moran M, et al. (2000): Galectin-1 induces partial TCR zeta-chain phosphorylation and antagonizes processive TCR signal transduction. J Immunol 165: 3722-3729.
11. Garín MI, Chu CC, Golshayan D, et al. (2007): Galectin-1: a key effector of regulation mediated by CD4+CD25+ T cells. Blood 109: 2058-2065.
12. Alhabbab R, Blair P, Smyth LA, et al. (2018): Galectin-1 is required for the regulatory function of B cells. Sci Rep 8: 2725.
13. Sandblad V, Morosi LG, Geffner JR, Rabinovich GA (2017): Galectin-1: a jack-of-all-trades in the resolution of acute and chronic inflammation. J Immunol 199: 3721-3730.
14. Pena C, Mirandola L, Figueroa JA, et al. (2014): Galectins as therapeutic targets for hematological malignancies: a hopeful sweetness. Ann Transl Med 2: 87.
15. Huang L, Banh B, Johnson BA 3rd, Mellor AL (2010): Dendritic cells, indoleamine 2,3 dioxygenase and acquired immune privilege. Int Rev Immunol 29: 133-155.
16. Ilarregui JM, Croci DO, Bianco GA, et al. (2009): Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10. Nat Immunol 10: 981-991.
17. Zeng H, Zhang R, Jin B, Chen L (2015): Type 1 regulatory T cells: a new mechanism of peripheral immune tolerance. Cell Mol Immunol 12: 566-571.
18. Cedeno-Laurent F, Opperman M, Barthel SR, et al. (2012): Galectin-1 triggers an immunoregulatory signature in Th cells functionally defined by IL-10 expression. J Immunol 188: 3127-3137.
19. Fayad L, Keating MJ, Reuben JM, et al. (2001): Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood 97: 256-263.
20. Alhakeem SS, McKenna MK, Oben KZ, et al. (2018): Chronic lymphocytic leukemia-derived IL-10 suppresses antitumor immunity. J Immunol 200: 4180-4189.
21. Tribulatti MV, Figini MG, Carabelli J, et al. (2012): Redundant and antagonistic functions of galectin-1, -3, and -8 in the elicitation of T cell responses. J Immunol 188: 2991-2999.
22. Liao W, Lin JX, Leonard WJ (2013): Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 38: 13-25.
23. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY (2005): A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 6: 1142-1151.